research reports and media, page-4121

Nah..we have covered it over a few iterations in the past...

V high level summary:

- Expensive
- Hit and miss, can work wonders on a few, others are meh.
- Individualised, hard to scale
- None really approved by authorities, maybe a couple but very specific applications


Might develop over time, our market is huge, there would be room for multiple players if Stem Cell area does improve and becomes cheaper/accessible/efficacious


There is prob more scope in eventual combination therapy...ie iPPS and stem cell together.


My thoughts, DYOR